AI research versus routine care
By ChatGPT Health. Educational synthesis prepared with AI assistance. Sources checked September 28, 2026. Clinically reviewed by Harvey Castro, MD, MBA, on September 28, 2026. Approved as educational content. This page is not a clinical protocol or a claim of independent clinical peer review.
Research results can identify a promising direction without establishing readiness for routine care. Match the conclusion to the stage and setting of evaluation.
Name the stage
An experiment may test a model on a dataset, examine it prospectively without changing care, evaluate it in a live workflow, or compare an intervention against usual care. These answer different questions. Record whether the system was used by real clinicians with actual constraints, and whether patient outcomes were measured.
Ask what the report makes visible
DECIDE AI focuses on reporting early clinical evaluation, while CONSORT AI extends reporting for trials involving AI. They help expose details needed to interpret an intervention, including how people and systems interact. They do not replace appraisal of bias or establish a product endorsement. DECIDE AI reporting guideline; CONSORT AI reporting guideline.
Apply the distinction to emerging uses
For drug discovery, separate a computational candidate from laboratory validation, a clinical trial and an authorized treatment. For a digital twin, ask which observations update the model, which predictions have been tested and what decision it informs. For synthetic data, ask whether it preserves relevant relationships and whether privacy and downstream performance have been evaluated. These are appraisal questions, not claims that a specific product has passed them.
Our translation checklist
Before describing research as clinical progress, record:
- The task, model version, dataset and intended users.
- The comparison and whether it reflects current practice.
- Independent evaluation and the populations it covers.
- The outcome measured and the uncertainty around the result.
- Missing evidence for patient benefit, workflow, cost and safety.
- Commercial interests and access to methods or data needed for scrutiny.
Keep the next step proportionate
A promising benchmark may justify a better experiment. A prospective workflow study may justify a larger comparison. A public explanation should say which step was completed and which remains. This keeps interest in emerging technology connected to evidence.
Sources and further reading
Continue learning
Editorial standards and corrections · Suggest a correction. Please do not send identifiable patient information.